Physician profile
Mohammad Ismail
NPI 1821052812
$13,006.17
in general payments reported to CMS, 2019-2025
65 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $1,127 · 2021: $1,886 · 2022: $2,197 · 2023: $2,749 · 2024: $2,175 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,134 · Travel and Lodging: $564 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,134.04 |
| Travel and Lodging | $563.90 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.31 | 2021-2025 | |
| Celgene Corporation | $843.95 | 2021-2025 | Zeposia |
| Biogen, INC. | $794.40 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Microvention, INC. | $704.40 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $700.54 | 2019-2025 | Austedo Xr, Austedo |
| Emd Serono, INC. | $616.24 | 2020-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $485.17 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $433.00 | 2019-2025 | Crexont, Rytary, Ongentys |
| Lilly USA, LLC | $422.37 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $409.01 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $366.87 | 2019-2025 | Nuplazid |
| Eisai INC. | $299.74 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $293.56 | 2020-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $290.57 | 2020-2025 | Epidiolex |
| Lundbeck LLC | $277.08 | 2021-2025 | Vyepti, Rexulti |
Show all 64 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.